Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 23;14(10):e082749.
doi: 10.1136/bmjopen-2023-082749.

Breast and endometrial safety of micronised progesterone versus norethisterone acetate in menopausal hormone therapy (PROBES): study protocol of a double-blind randomised controlled trial

Christina Lundell  1 , Nikolaos Stergiopoulos  1 , Liselott Blomberg  1 , Dorina Ujvari  2 , Ina Schuppe-Koistinen  1 , Helena Kopp-Kallner  1 , Stavros I Iliadis  3 , Alkistis Skalkidou  4 , Angelica Linden Hirschberg  5
Affiliations

Breast and endometrial safety of micronised progesterone versus norethisterone acetate in menopausal hormone therapy (PROBES): study protocol of a double-blind randomised controlled trial

Christina Lundell et al. BMJ Open. .

Abstract

Introduction: Data suggest that micronised progesterone (mP) in menopausal hormone therapy is safer for the breast than synthetic progestins, while protection of the endometrium appears to be less effective. However, comparative randomised trial data are lacking. The objective of the Progesterone Breast Endometrial Safety Study is to investigate breast and endometrial safety of mP versus norethisterone acetate (NETA) in continuous combination with oral oestrogen.

Methods and analysis: This multicentre trial, conducted at three University Hospitals in Stockholm and Uppsala, Sweden, consists of two phases: part 1 focuses on breast safety and is designed as a double-blind, randomised controlled trial. 260 postmenopausal women will be randomised to 100 mg mP or 0.5 mg NETA per day in continuous combination with 1 mg oestradiol. The primary objective is to compare the treatments with respect to percentage change in mammographic breast density after 12-month treatment. Secondary outcomes are breast proliferation, endometrial histology and proliferation, bleeding pattern, gut and vaginal microbiome, hormone levels and coagulation and metabolic factors, mood, and health-related quality of life. Part 2 features an open, single-arm design to study endometrial safety of 1-year treatment with mP in continuous combination with oestradiol on endometrial pathology (hyperplasia and cancer). We will treat 260 additional women with 100 mg mP/1 mg oestradiol resulting in an endometrial safety population of 390 women. The total number of participants in part 1 and part 2 will be 520.

Ethics and dissemination: The study protocol was approved by the Swedish Ethical Review Authority (2021-03033) on 29 June 2021 with amendment (2023-01480-02, protocol version 3.1) on 14 March 2023. Results of the study will be published in peer-reviewed journals and presented at scientific meetings.

Trial registration number: NCT05586724.

Keywords: Community gynaecology; Randomized Controlled Trial; Sex steroids & HRT.

PubMed Disclaimer

Conflict of interest statement

Competing interests: This is an investigator-initiated study. The company Besins healthcare Ireland has provided financial support and study medication but has not been involved in the preparation of the study protocol and will not be involved in the evaluation and publication of study results.

Figures

Figure 1
Figure 1. Flow diagram of part 1: breast safety—a double-blind, randomised study design. mP, micronised progesterone; NETA, norethisterone acetate.
Figure 2
Figure 2. Flow diagram of part 2: endometrial safety—an open single-armed study design. mP, micronised progesterone.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ettinger B, Friedman GD, Bush T, et al. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol. 1996;87:6–12. doi: 10.1016/0029-7844(95)00358-4. - DOI - PubMed
    1. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933–41. doi: 10.7326/0003-4819-133-12-200012190-00008. - DOI - PubMed
    1. LeBlanc ES, Janowsky J, Chan BK, et al. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001;285:1489–99. doi: 10.1001/jama.285.11.1489. - DOI - PubMed
    1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33. doi: 10.1001/jama.288.3.321. - DOI - PubMed
    1. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523–34. doi: 10.1056/NEJMoa030808. - DOI - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources